Thomas D. Rodgers

Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer

Eric S. Kim, Andrea Baran, Esther Liu Mondo et al. · PLoS ONE · 2017 · 20 citations · Full text

Medicine, Oncology, Pharmacology +13

FRI0370 Efficacy and safety of lesinurad (RDEA594), a novel URAT1 inhibitor, in combination with allopurinol in allopurinol-refractory gout patients: Results from a randomized, blinded, placebo-controlled, phase 2b extension study

Fernando Pérez-Ruiz, John S. Sundy, Eswar Krishnan et al. · Annals of the Rheumatic Diseases · 2012 · 16 citations

Pharmacy, Pharmacology, Pharmacotherapy +10

RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Grzegorz S. Nowakowski, Thomas D. Rodgers, Dario Marino et al. · Journal of Clinical Oncology · 2020 · 14 citations

Medicine, Oncology, Pharmacotherapy +14